Taiwan Cohort - Chronic ThromboEmbolic Pulmonary Hypertension Registry
试验速览
- 阶段
- 不适用
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- To investigate the geodemographics of CTEPH in Taiwan
研究概览
简要总结
The diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) is difficult for numerous reasons and is related with a poor prognosis. In Taiwan, the incidence of CTEPH and its clinical features are unknown. This study aims at evaluating the prevalence, clinical characteristics, and management of CTEPH in a Taiwanese cohort.
Primary objective:
- To investigate the geodemographics of CTEPH in Taiwan
Secondary objectives:
- To characterize the demographics and clinical presentation of patients with CTEPH
- To describe the real-world management and treatment outcome of patients with CTEPH
- To identify the risk factors of CTEPH
- To assess the relationship between risk factors/patients' characteristics and clinical outcomes for CTEPH
- To evaluate the prognosis of CTEPH in Taiwan using survival assessment
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Right heart catheterization (RHC) results that are in line with both of the following haemodynamic levels:
- •Mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg at rest AND Pulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg
- •Confirmation of CTEPH diagnosis by one of the following as recommended by standard guidelines:
- •At least 1 (segmental) perfusion defect(s) in ventilation-perfusion (V/Q) / perfusion scan OR Pulmonary artery obstruction seen by multidetector computed tomography (MDCT) angiography or conventional pulmonary cineangiography.
- •Presence of pulmonary hypertension or evidence of pulmonary thromboembolism after at least 3 months of anticoagulation treatment.
排除标准
- •not written informed consent
- •not meet inclusion criteria
结局指标
主要结局
To investigate the geodemographics of CTEPH in Taiwan
时间窗: recruiting period two years
variables of interest also include (1) patients characteristics, such as demographics and medical history; (2) clinical features and diagnosis records, such as risk factors, comorbidities, CTEPH diagnosis data, concomitant conditions; (3) management of CTEPH, including surgery and medication; and (4) clinical outcome including clinical assessment results, survival status, and clinical worsening related to CTEPH.
次要结局
- To characterize the demographics and clinical presentation of patients with CTEPH - To describe the real-world management and treatment outcome of patients with CTEPH - To identify the risk factors of CTEPH - To assess the relationship between risk f(recruiting period two years)